Please login to the form below

Not currently logged in

Novartis heart drug may see novel pricing plan

Novartis daySwiss firm looking to risk share with payers based on clinical outcomes

Roche and Evotec’s Alzheimer’s drug ineffective

Alzheimer's disease brain scanSembragiline failed to show cognitive and memory benefits

Celgene and Juno announce ten-year cancer deal

Celgene buildingThe firms’ pact will focus on the new area of immunotherapy

Merck plans expanded filing for Emend this year

Merck and Co - US headquartersNausea and vomiting therapy more effective than placebo in 1000-patient trial

Opdivo approved via UK’s early drug access scheme

Successful PartnershipsBristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

Roche planning ocrelizumab filings in early 2016

Roche Basel SwitzerlandFirm claims MS candidate outperformed Merck Serono’s Rebif in two phase III trials

Lilly and Immunocore ink immunotherapy R&D deal

Eli Lilly HQFirms will test new joint therapy in patients with melanoma

Sobi wins European approval for oral form of orphan drug Orfadin

Swedish Orphan Biovitrum (Sobi)Expands treatment options for rare genetic disease HT-1

Who is the marketer of the future?

How to prepare for biopharma marketing in 2020 and beyond

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Toast TV

Toast TV are experts in communicating the needs of our clients through engaging and beautifully crafted live action and animated...

Latest intelligence

Is telehealth delivering on its promises?
Using new digital technologies to help patients see their doctors online and not need to attend their surgery can help save time and money - but just how well is...
Channel purpose, change lives
GCI Health's Laura Starr on the power of creativity in health and wellness, all founded upon authentic brand purpose....
Wearables: the tangible product of the patient revolution
As the relationship between the patient and his doctor evolve, we look at how new technology is playing its part...